Entropy reports sustained improvement in binge-eating study as it expands TRP-8803 trials
ENP: $0.030 +0.00% · MC: $47M
Entropy Neurodynamics reported that all six patients in the first cohort of its treatment-resistant binge-eating study maintained clinically meaningful improvement at 12 weeks, with half experiencing complete remission and weekly binge-eating episodes remaining 73% below baseline. The company also secured ethics approval for a 72-patient study across eight indications, agreed GMP manufacturing with BioCina and signed a preliminary agreement with UCSF for a potential US depression study. After quarter-end, the next study cohort began testing a shorter infusion protocol, with topline results expected by the end of 2026.

Comments